Scolyer received a combination of anti-PD-1 (nivolumab; Opdivo, Bristol Myers Squibb), anti-CTLA-4 (ipilimumab; Yervoy, Bristol Myers Squibb) and anti-LAG3 (relatlimab; Opdualag, Bristol Myers ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 ...

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer's mighty Eylea in the US – and could soon start making inroads against its rival ...

I have good experience with nivolumab/relatlimab, [although] I don't have too many patients. I’ve treated a lot with nivolumab/ipilimumab. So far with nivolumab/relatlimab I haven’t had any problems, ...

discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series. Relatlimab/Nivolumab in Melanoma Improves Brain ...

Laila Maidan is a Tech and Investing reporter at MarketWatch. She covers the rapid developments in the sector along with actionable investment recommendations and deep dives into valuations.